Topic Review
AMPT
Alpha-methyl-p-tyrosine (AMPT) is a tyrosine hydroxylase enzyme inhibitor and is therefore a drug involved in inhibiting the catecholamine biosynthetic pathway. AMPT inhibits tyrosine hydroxylase whose enzymatic activity is normally regulated through the phosphorylation of different serine residues in regulatory domain sites. Catecholamine biosynthesis starts with dietary tyrosine, which is hydroxylated by tyrosine hydroxylase and it is hypothesized that AMPT competes with tyrosine at the tyrosine-binding site, causing inhibition of tyrosine hydroxylase. It has been used in the treatment of pheochromocytoma. It has been demonstrated to inhibit the production of melanin.
  • 320
  • 25 Oct 2022
Topic Review
Amsacrine
Amsacrine, an anticancer drug first synthesised in 1970 by Professor Cain and colleagues, showed excellent preclinical activity and underwent clinical trial in 1978 under the auspices of the US National Cancer Institute, showing activity against acute lymphoblastic leukaemia.
  • 575
  • 25 Feb 2021
Topic Review
AMT Gene
aminomethyltransferase
  • 446
  • 24 Dec 2020
Topic Review
Amygdala
The amygdala is one of the areas in the brain involved in the development of PTSD as the starting point for the process of activation of the hypothalamo–pituitary axis and the cascade of physiological responses to acute stress. An appropriate response to acute stress is a vital adaptive mechanism, but its prolongation causes various biopsychosocial (previously, psychosomatic) disorders. Chronic stress leads to higher expression of CRH/CRF in the CE and BLA, which has an anxiogenic effect.
  • 3.6K
  • 13 Jul 2021
Topic Review
Amygdala Neuroinflammation and Psychiatric Disorders
Depression and anxiety disorder are the most common mental diseases affecting hundreds of millions of people worldwide. The comorbidity rate of anxiety disorder and depression is very high, with 74% of depressed patients having anxiety symptoms, while 61% of anxious patients have depression symptoms. Stress exposure is widely accepted as a critical contributing factor to psychological and neuropathological disorders. Especially during the COVID-19 pandemic, the high pressure of increasingly demanding work and life has led to a sharp rise in the incidence of mental diseases. Inflammation induces psychological and neuropathological disorders by influencing neuronal excitability, neurotransmitter release, receptor, and transporter expression through peripheral hormones and autonomic responses. A number of animal and human studies have revealed that the amygdala, ventral hippocampus, and medial prefrontal cortex (mPFC) are extensively involved in the occurrence of anxiety, depression, and related behavioral regulation. Among them, the amygdala, one of the kernel brain regions mediating stress-coping located in the deep temporal lobe, is considered the hub center for processing emotionally salient stimuli and implementing appropriate behavioral responses.
  • 776
  • 23 Feb 2023
Topic Review
Amyloid Beta Oligomers
Amyloid beta (Aβ) oligomers are the most neurotoxic aggregates causing neuronal death and cognitive damage. A detailed elucidation of the aggregation pathways from oligomers to fibril formation is crucial to develop therapeutic strategies for Alzheimer’s disease (AD). This review mainly focused on future perspective of Aβ peptide research using computer simulations.
  • 547
  • 27 Oct 2021
Topic Review
Amyloid Fragmentation and Disaggregation in Yeast and Animals
Amyloids are filamentous protein aggregates that are associated with a number of incurable diseases, termed amyloidoses. Amyloids can also manifest as infectious or heritable particles, known as prions. While just one prion is known in humans and animals, more than ten prion amyloids have been discovered in fungi. The propagation of fungal prion amyloids requires the chaperone Hsp104, though in excess it can eliminate some prions. Even though Hsp104 acts to disassemble prion fibrils, at normal levels it fragments them into multiple smaller pieces, which ensures prion propagation and accelerates prion conversion. Animals lack Hsp104, but disaggregation is performed by the same complement of chaperones that assist Hsp104 in yeast—Hsp40, Hsp70, and Hsp110. Exogenous Hsp104 can efficiently cooperate with these chaperones in animals and promotes disaggregation, especially of large amyloid aggregates, which indicates its potential as a treatment for amyloid diseases. However, despite the significant effects, Hsp104 and its potentiated variants may be insufficient to fully dissolve amyloid.
  • 283
  • 20 Jan 2022
Topic Review
Amyloid Oligomers
Amyloid oligomers are considered to be potential targets for the development of therapeutic strategies for a wide range of neurodegenerative diseases. However, due to the low-populated, transient, and heterogeneous nature of amyloid oligomers, they are hard to characterize by conventional bulk methods. The development of single molecule approaches provides a powerful toolkit for investigating these oligomeric intermediates as well as the complex process of amyloid aggregation at molecular resolution.
  • 441
  • 21 Apr 2021
Topic Review
Amyloid Pathologies
Protein aggregation into amyloid fibrils affects many proteins in a variety of diseases, including neurodegenerative disorders, diabetes, and cancer. Physicochemically, amyloid formation is a phase transition process, where soluble proteins are transformed into solid fibrils with the characteristic cross-β conformation responsible for their fibrillar morphology.
  • 416
  • 11 Apr 2022
Topic Review
Amyloid Precursor Protein
Amyloid precursor protein (APP) is an integral membrane protein expressed in many tissues and concentrated in the synapses of neurons. Its primary function is not known, though it has been implicated as a regulator of synapse formation, neural plasticity, antimicrobial activity , and iron export. APP is best known as the precursor molecule whose proteolysis generates amyloid beta (Aβ), a polypeptide containing 37 to 49 amino acid residues, whose amyloid fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients.
  • 622
  • 25 Nov 2022
  • Page
  • of
  • 1746
Video Production Service